| 钟露慧,熊 英,崔 晋,等.抗EGFR再挑战在转移性结直肠癌三线治疗中的应用研究进展[J].肿瘤学杂志,2024,30(10):817-824. |
| 抗EGFR再挑战在转移性结直肠癌三线治疗中的应用研究进展 |
| Research Progress on Anti-EGFR Rechallenge for the Third-Line Therapy of Metastatic Colorectal Cancer |
| 投稿时间：2024-06-04 |
| DOI：10.11735/j.issn.1671-170X.2024.10.B004 |
|
 |
| 中文关键词: 结直肠肿瘤 肿瘤转移 表皮生长因子受体 再挑战 RAS野生型 |
| 英文关键词:colorectal neoplasmas tumor metastasis epidermal growth factor receptor rechallenge RAS wild-type |
| 基金项目: |
|
| 摘要点击次数: 106 |
| 全文下载次数: 27 |
| 中文摘要: |
| 摘 要：表皮生长因子受体（epidermal growth factor receptor，EGFR）单克隆抗体是治疗转移性结直肠癌患者的有效一线药物。然而，抗EGFR治疗后获得性耐药的出现限制了EGFR抑制剂在转移性结直肠癌持续治疗中的应用。基于分子生物学的研究，抗EGFR再挑战策略在RAS/BRAF野生型转移性结直肠癌患者二线治疗后的临床管理中具有潜在活性。全文综述了抗EGFR再挑战策略在转移性结直肠癌三线治疗中的疗效及其相关毒性，并探讨了疗效预测因素的研究进展，为临床实践和科学研究提供新的视角。 |
| 英文摘要: |
| Abstract： The epidermal growth factor receptor (EGFR) monoclonal antibody is an effective first-line drug for metastatic colorectal cancer patients. However， the emergence of acquired resistance after anti-EGFR therapy limits the use of EGFR inhibitors in the sustained treatment of metastatic colorectal cancer. Based on molecular biology research， the anti-EGFR rechallenge strategy has potential activity in clinical management of RAS/BRAF wild-type metastatic colorectal cancer patients after second-line treatment. This paper reviews the efficacy and related toxicity of the anti-EGFR rechallenge strategy in the third-line treatment of metastatic colorectal cancer， as well as the prediction factors for efficay， to provid a new perspective for clinical practice and scientific research. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |